Research programme: tuberculosis therapies - Daiichi Sankyo/Global Alliance for TB Drug Development
Latest Information Update: 28 Dec 2019
Price :
$50 *
At a glance
- Originator Daiichi Sankyo Company; Global Alliance for TB Drug Development
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Tuberculosis in Japan
- 04 Nov 2015 Early research in Tuberculosis in Japan (unspecified route)